A novel vaccine strategy using virus-like particles (VLPs) could provide stronger and longer-lasting influenza vaccines with a significantly shorter development and production time than current ones, allowing public health authorities to react more quickly in the event of a potential pandemic.
Ted Ross, Ph.D., an assistant professor at the University of Pittsburgh's Center for Vaccine Research, will present his laboratory's latest data on the efficacy of VLP vaccines for potential pandemic strains, such as H5N1 and 1918 influenza, today at the 109th General Meeting of the American Society for Microbiology in Philadelphia.
"Virus-like particles look just like a live virus, but they are hollow shells without a genome inside and they cannot reproduce," Ross explained. "Because they look like the virus, they evoke a more robust immune response against the real thing."
Ross and his colleagues have already made VLP vaccines that have been tested in early clinical trials and appear to provide complete protection against both the H5N1 avian influenza virus and the 1918 Spanish influenza virus.
"There is a debate in the influenza community about priming the human population for potential pandemic strains such as H5N1 or 1918," Ross said. "Some researchers advocate adding these strains to the annual flu vaccine. They might not match the next pandemic flu strain exactly, but could provide some of protection."
Others contend that it might be premature, as well as costly, to vaccinate people against a virus that may never emerge, he said.
The current injectable vaccine for seasonal influenza is a trivalent, inactivated vaccine. It consists of three different influenza strains that are grown in eggs and then inactivated, or killed, by chemicals that break them into tiny pieces. Because they no longer look like the circulating virus, conventionally made vaccines strains do not elicit as strong an immune response as VLP vaccines. Because it is made with live, attenuated virus, the inhaled, mist-based vaccine can elicit a strong immune response but can also increase the risk of side effects.
VLPs can be quickly and easily produced in several ways, including growing them in cell cultures or in plants. Also, if the genes in the disease virus are identified, then researchers can generate particles for a vaccine without an actual sample of the agent.
"The sequence for the recent H1N1 'swine flu' virus was online and available to scientists long before physical samples could be delivered," Dr. Ross noted. "It would have been possible to produce VLPs in quantity in as little as 12 weeks while conventional vaccines require physical samples of the virus and production can take approximately nine months."
One VLP-based vaccine already is on the market, namely the human papilloma virus (HPV) vaccine.
More information on this and other presentations can be found online in the 109th ASM General Meeting Press Kit at http://tinyurl.com/asmnewsroom or by contacting Jim Sliwa ( firstname.lastname@example.org or 202.942.9297) in the ASM Office of Communications. Follow media events at the meeting via Twitter at http://www.twitter.com/ASMNewsroom.
The American Society for Microbiology, headquartered in Washington, D.C., is the largest single life science association, with 42,000 members worldwide. Its members work in educational, research, industrial, and government settings on issues such as the environment, the prevention and treatment of infectious diseases, laboratory and diagnostic medicine, and food and water safety. The ASM's mission is to gain a better understanding of basic life processes and to promote the application of this knowledge for improved health and economic and environmental well-being.
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.